F2G Moves UK Headquarters to MediaCity

MANCHESTER, United Kingdom, May 18, 2023 – MediaCity and F2G are pleased to announce, F2G Ltd., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening fungal infections with a high unmet medical need, has moved its UK headquarters to MediaCity in Salford, Greater Manchester.  

The new F2G office space within the flexible ARRIVE workspace in MediaCity’s Blue tower allows the company room for future expansion, and access to the White and Tomorrow facilities including additional space for hosting events for its entire UK workforce and partners.

Stephen Kirk, Head of Property for MediaCity, said, “F2G’s work in the treatment of life threatening fungal infections is groundbreaking and as a world class tech, digital and innovation hub which attracts many dynamic sectors from fintech and gaming to medical science we’re delighted F2G has based its UK headquarters here.”

Mike Birch, Chief Operating Officer of F2G, added, “MediaCity was an easy choice to make for our new UK headquarters because of its proximity to our research facility in Eccles and the sense of community that has been created amongst the companies that call this place home. We look forward to being an active member of the MediaCity community.”

Manchester is a big part of F2G’s history – its major scientific discoveries around the new class of antifungals called, orotomides, were made in a research lab less than a mile away from MediaCity. The company was established in Manchester leveraging the teams’ fungal genetics expertise to discover cellular targets to use in drug discovery. For twenty years the team has been on a journey to unlock the potential of its science and is now on the verge of bringing an entirely new class of systemic antifungal agents to treat patients with life-threatening systemic fungal infections.

About MediaCity
MediaCity is a waterside community that’s part of Salford Quays in Salford, Greater Manchester. It’s home to some of the world’s most exciting creative, tech and media brands, from BBC North and ITV to Ericsson, The Hut Group Group, Kellogg’s and over 250 creative and tech businesses. Three education establishments are based there, including the University of Salford’s dedicated MediaCity campus, while at its heart is HOST, the Home of Skills & Technology, which supports innovators in data, analytics, cybersecurity, AI, gaming and immersive technologies. Alongside a growing roster of local, independent food, drink and retail operators is a dedicated shopping centre, parks and public spaces, and one of the UK’s most visited arts centres, The Lowry. Sustainability is core to MediaCity’s future: home to the UK’s largest cluster of net zero carbon buildings, it has two dedicated Metrolink tram stops, while 100% of its energy comes from renewable sources. It is also a popular residential neighbourhood, with MediaCity as a whole set to double in size within the next decade. 

MediaCity is a joint venture between Peel L&P and Landsec. Together, their inclusive and collaborative approach to the development of MediaCity will ensure that it grows into a community united by creativity, and a place of play, imagination, and innovation. 

About F2G
F2G is a biotech company with operations in the UK, US, and Austria focused on the discovery and development of novel therapies to treat potentially life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides which selectively target a key enzyme in the de novo pyrimidine biosynthesis pathway. This is a completely different mechanism from that of the currently marketed antifungal agents and gives the orotomides fungicidal activity against a broad range of rare and resistant fungal mold infections. For more information, please visit: www.f2g.com

Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also, for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Media Contact:
Gloria Gasaatura
LifeSci Communications
+1 646 970 4688

Scroll to Top